Prescription required. Can not be split. Product of India. Shipped from Mauritius. Farxiga is also marketed internationally under the name Forxiga.
Prescription required. Can not be split. Product of India. Shipped from Mauritius.
Prescription required. Can not be split. Product of India. Shipped from Mauritius. Farxiga is also marketed internationally under the name Forxiga.
Prescription required. May be split. Product of India. Shipped from Mauritius.
Farxiga (dapagliflozin) and Forxiga are oral medications used to manage blood sugar control in patients with Type 2 Diabetes. Farxiga (dapagliflozin) belongs to a class of drugs known as “sodium-glucose co-transporter 2 (SGLT2) inhibitors.” These work by helping the kidneys remove glucose from the bloodstream through the urine.
Farxiga is also prescribed to reduce the risk of hospitalization for heart failure and to reduce the risk of chronic kidney disease progression.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
Similar to other prescription medications, healthcare providers and patients must consider many factors before and after starting therapy with Farxiga. There are some important precautions associated with Farxiga.
Farxiga is not recommended for patients with Type 1 Diabetes.
Farxiga activity is influenced by and can affect kidney function. Assessing kidney function before and after starting Farxiga is critical.
Farxiga increases the amount of sugar in urine, which can raise the risk of genital fungal infections and bacterial urinary tract infections. If an infection occurs, it should be treated promptly. If left untreated or they become recurrent, these infections can increase the risk of further complications.
Farxiga can cause more urine to be produced, which may contribute to a higher risk of dehydration due to fluid loss. It’s important to ensure adequate fluid intake, particularly in hot weather or during exercise.
Especially when added to insulin or medications that increase insulin release (e.g., glipizide or glimepiride), Farxiga can increase the risk of dangerously low blood sugars.
Because fluid is removed from the bloodstream in the form of urine, blood pressures can become lower. Monitoring blood pressure is important while taking Farxiga. If you feel dizzy or light-headed, discuss this with your healthcare provider.
Here are other rare but serious risk factors associated with taking Farxiga (dapagliflozin):
Warning/Precaution | Additional Risk Information |
Ketoacidosis Risk | There are rare reports of ketoacidosis in patients using SGLT2 inhibitors, including Farxiga, even if blood glucose levels are <250 mg/dL. Symptoms include excessive thirst, frequent urination, nausea, and abdominal pain. |
Volume Depletion Risk | Farxiga has been known to cause intravascular volume depletion, leading to symptomatic low blood pressure (e.g., dizziness or light-headedness) or changes in kidney function. Patients with impaired kidney function, elderly patients, or those on loop diuretics (e.g., furosemide) are at increased risk. |
Urinary Tract Infections Risk | Increased risk of serious urinary tract infections may occur, including infection entering the bloodstream or kidney infections. Monitor for signs and symptoms of urinary tract infections and treat infections promptly. |
Hypoglycemia Risk with Insulin/Secretagogues | Increased risk of hypoglycemia (dangerously low blood sugar) when combined with insulin or insulin secretagogues. It may be necessary to lower the dose of insulin or secretagogue (e.g., sulfonylureas like glipizide or glimepiride). Symptoms of hypoglycemia include dizziness, confusion, and sweating. |
Necrotizing Fasciitis Risk | Rare cases of necrotizing fasciitis (Fournier's gangrene) have been reported. Symptoms include pain or tenderness, erythema, and swelling in the genital or perianal area, fever, and malaise. Treat infections promptly and discuss recurrent infections if they occur. |
Here are general dosage recommendations for Farxiga (dapagliflozin):
Treatment of Condition | Initial Dose | Maintenance Dose | Maximum Dose |
Type 2 Diabetes | 5 mg once daily | May increase to 10 mg once daily | 10 mg once daily |
Chronic Kidney Disease | 10 mg once daily | 10 mg once daily | 10 mg once daily |
Heart Failure | 10 mg once daily | 10 mg once daily | 10 mg once daily |
Renal Impairment (eGFR <45 mL/min/1.73 m²) | Not recommended | Not recommended | Not recommended |
Common side effects include the following:
Genital yeast infections
Urinary tract infections
Nasopharyngitis (cold or flu-like respiratory symptoms)
If you experience any of these side effects, discussing your treatment with your healthcare provider is important.
Other common questions:
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This class of medications helps manage blood sugar levels by causing the kidneys to remove more glucose in the urin
The content on this page is for informational and educational purposes only and does not constitute professional medical advice. Patients should not use the information presented on this page for diagnosing a health-related issue or disease. Before taking any medication or supplements, patients should always consult a physician or qualified healthcare professional for medical advice or information about whether a drug is safe, appropriate or effective.